Title
Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey
Date Issued
2008
Access level
open access
Resource Type
journal article
Author(s)
Rodriguez J.J.L.
Ferri C.P.
Acosta D.
Huang Y.
Jacob K.S.
Krishnamoorthy E.S.
Salas A.
Sosa A.L.
Acosta I.
Dewey M.E.
Gaona C.
Jotheeswaran A.T.
Li S.
Rodriguez D.
Rodriguez G.
Kumar P.S.
Valhuerdi A.
Prince M.
Universidad Peruana Cayetano Heredia
Publisher(s)
Elsevier B.V.
Abstract
Background: Studies have suggested that the prevalence of dementia is lower in developing than in developed regions. We investigated the prevalence and severity of dementia in sites in low-income and middle-income countries according to two definitions of dementia diagnosis. Methods: We undertook one-phase cross-sectional surveys of all residents aged 65 years and older (n=14 960) in 11 sites in seven low-income and middle-income countries (China, India, Cuba, Dominican Republic, Venezuela, Mexico, and Peru). Dementia diagnosis was made according to the culturally and educationally sensitive 10/66 dementia diagnostic algorithm, which had been prevalidated in 25 Latin American, Asian, and African centres; and by computerised application of the dementia criterion from the Diagnostic and Statistical Manual of Mental Disorders (DSM IV). We also compared prevalence of DSM-IV dementia in each of the study sites with that from estimates in European studies. Findings: The prevalence of DSM-IV dementia varied widely, from 0·3% (95% CI 0·1-0·5) in rural India to 6·3% (5·0-7·7) in Cuba. After standardisation for age and sex, DSM-IV prevalence in urban Latin American sites was four-fifths of that in Europe (standardised morbidity ratio 80 [95% CI 70-91]), but in China the prevalence was only half (56 [32-91] in rural China), and in India and rural Latin America a quarter or less of the European prevalence (18 [5-34] in rural India). 10/66 dementia prevalence was higher than that of DSM-IV dementia, and more consistent across sites, varying between 5·6% (95% CI 4·2-7·0) in rural China and 11·7% (10·3-13·1) in the Dominican Republic. The validity of the 847 of 1345 cases of 10/66 dementia not confirmed by DSM-IV was supported by high levels of associated disability (mean WHO Disability Assessment Schedule II score 33·7 [SD 28·6]). Interpretation: As compared with the 10/66 dementia algorithm, the DSM-IV dementia criterion might underestimate dementia prevalence, especially in regions with low awareness of this emerging public-health problem. Funding: Wellcome Trust (UK); WHO; the US Alzheimer's Association; and Fondo Nacional De Ciencia Y Tecnologia, Consejo De Desarrollo Cientifico Y Humanistico, and Universidad Central De Venezuela (Venezuela). © 2008 Elsevier Ltd. All rights reserved.
Start page
464
End page
474
Volume
372
Issue
9637
Language
English
OCDE Knowledge area
Psiquiatría
Scopus EID
2-s2.0-48849102173
PubMed ID
Source
The Lancet
Resource of which it is part
The Lancet
ISSN of the container
01406736
Sponsor(s)
The 10/66 Dementia Research Group's research has been funded by the Wellcome Trust Health Consequences of Population Change Programme (GR066133—prevalence phase in Cuba and Brazil; GR08002—incidence phase in Peru, Mexico, Argentina, Cuba, Dominican Republic, Venezuela, and China); WHO (India, Dominican Republic, and China); the US Alzheimer's Association (IIRG–04–1286—Peru, Mexico, and Argentina); and Fondo Nacional De Ciencia Y Tecnologia, Consejo De Desarrollo Cientifico Y Humanistico, and Universidad Central De Venezuela (Venezuela). The Rockefeller Foundation supported our dissemination meeting at their Bellagio Centre. Alzheimer's Disease International (ADI) has provided support for networking and infrastructure. The 10/66 Dementia Research Group works closely with ADI, the non-profit federation of 77 Alzheimer associations around the world. ADI is committed to strengthening Alzheimer associations worldwide, raising awareness regarding dementia and Alzheimer's Disease, and advocating for more and better services for people with dementia and their caregivers. ADI is supported in part by grants from GlaxoSmithKline, Novartis, Lundbeck, Pfizer, and Eisai.
Sources of information: Directorio de Producción Científica Scopus